{"id":"W3081807968","doi":"10.3310/hta24400","title":"Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT","year":2020,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics","funders":"National Institute for Health and Care Research; Cancer Research UK; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Daiichi Sankyo Europe; Health Technology Assessment Programme; Genentech; Servier; Pfizer; Eisai; Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical endpoint; Internal medicine; Randomized controlled trial; Oncology; Metastatic breast cancer; Adjuvant; Cancer; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004172355,0.0003173923,0.0007249117,0.0002299616,0.0002543071,0.00002228423,0.0003636289,0.0002685005,0.000160443],"category_scores_gemma":[0.00004427513,0.0002253798,0.00006323211,0.001035132,0.0004067222,0.00008834496,0.000188729,0.001860534,0.00003020369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002658897,"about_ca_system_score_gemma":0.002859456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005775564,"about_ca_topic_score_gemma":0.002711098,"domain_scores_codex":[0.9968278,0.0001674235,0.000504751,0.0006896628,0.0008422602,0.0009681127],"domain_scores_gemma":[0.9985104,0.00009889852,0.0001994341,0.000589665,0.0002447249,0.0003569251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003246557,0.0006937179,0.9274959,0.000237762,0.0001663389,0.00009334595,0.001546663,0.0000193632,0.0000459606,0.0001607196,0.00110778,0.0651859],"study_design_scores_gemma":[0.008789921,0.007024636,0.9797515,0.0003536671,0.00003886064,0.000009938109,0.002017177,0.0003251917,0.00007757741,0.00000778436,0.001403436,0.0002003579],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8482097,0.0004117152,0.000140365,0.1472412,0.0002362629,0.002950326,0.0001826381,0.0001768794,0.0004509238],"genre_scores_gemma":[0.9961743,0.0003978679,0.0006512181,0.001922155,0.0001008216,0.0006494609,0.00003124734,0.00005423065,0.00001863864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1479647,"threshold_uncertainty_score":0.919072,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02579314638784396,"score_gpt":0.3727333279500021,"score_spread":0.3469401815621582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}